Compare AbbVie Inc (ABBV) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Microsoft — how do they compare? AbbVie Inc trades at $249.02 (market cap $438.19B), while Microsoft trades at $501.88 (market cap $3.76T). The key difference: Microsoft is far larger — about 8.6× AbbVie Inc's market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | MSFT | |
|---|---|---|
Market Cap | $438.19B | $3.76T |
Sector | Health | Technology |
52-Week High | $263.58 | $542.07 |
52-Week Low | $197.38 | $352.83 |
Enterprise Value | $502.45B | $3.74T |
Dividend Yield | 2.79% | 0.72% |
Volume | — | 36,654,621 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.94, up 1.59% with bullish technical signals and strong analyst support. The company demonstrates solid revenue growth to $61.16B in 2025, though net margins have compressed to 6.9%. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $3.65 surpassing estimates. Technical indicators show bullish momentum with the current price near resistance at $249, while RSI suggests potential oversold conditions at lower timeframes.
AbbVie presents a compelling investment case with 71% analyst buy ratings and a $281.33 price target offering 12.6% upside. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, though patent cliffs in the 2030s and regulatory risks require monitoring. The company's dividend growth streak and robust pipeline support long-term value, but investors should weigh execution risks against current valuation multiples.
Microsoft (MSFT) trades at $503.81, up 0.76% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust earnings beats in recent quarters, with Q2 2026 EPS of $4.74 exceeding the $4.24 estimate. Revenue growth is steady, reaching $281.72B in 2025, supported by a net income margin of 40.31%. Analyst consensus is overwhelmingly positive, with 80.49% buy ratings and a $553.70 price target. Recent news highlights AI leadership and Azure momentum, though concerns over capital expenditures persist.
Outlook remains favorable with AI-driven growth and cloud expansion, but risks include high valuation (P/E 28.19) and competitive pressures. Investment opportunity lies in sustained earnings momentum and dividend stability, while volatility from tech sector shifts and macroeconomic factors warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
